Brunasso Alexandra M G, Burlando Martina, Amoruso Fabrizio, Arancio Luisa, Malara Giovanna, Manzo Raffaella, Montesu Maria Antonia, Caldarola Giacomo
Department of Internal Medicine, Villa Scassi Hospital ASL3, 16100 Genoa, Italy.
Department of Dermatology, Dipartimento di Scienze Della Salute, DISSAL, University of Genoa, 16100 Genoa, Italy.
Biomedicines. 2023 Jun 20;11(6):1769. doi: 10.3390/biomedicines11061769.
Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody which targets the p19 subunit of interleukin-23 and it is currently licensed also as systemic therapy for moderate to severe plaque psoriasis. Here, we present eight cases of patients with moderate to severe psoriasis treated with risankizumab with a significant efficacy in the remission of the disease. Our cases represent a real-world clinical setting and provide a valuable adjunct to results obtained in the selected patients usually included in controlled clinical trials. In our cases, risankizumab rapidly improved clinical manifestations and relieved symptoms in patients with moderate to severe psoriasis, regardless of the presence of comorbidities or the location of the plaques in special sites, and without any safety concerns.
银屑病是一种慢性炎症性疾病，全球有2950万人受其影响，它会对生活质量产生负面影响，尤其是当它影响到特殊部位时，如指甲、面部、手掌和脚底，或褶皱部位。瑞莎珠单抗是一种靶向白细胞介素-23 p19亚基的人源化单克隆抗体，目前也被批准作为中重度斑块状银屑病的全身治疗药物。在此，我们报告8例中重度银屑病患者接受瑞莎珠单抗治疗后疾病缓解效果显著的病例。我们的病例代表了真实世界的临床情况，为通常纳入对照临床试验的选定患者所获得的结果提供了有价值的补充。在我们的病例中，瑞莎珠单抗能迅速改善中重度银屑病患者的临床表现并缓解症状，无论患者是否存在合并症或斑块在特殊部位的位置，且无任何安全问题。
